A 6 Months, Randomized, Multicenter, Parallel-group, Open-label Study to Evaluate the Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With Relapsing-remitting Multiple Sclerosis
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 03 May 2013
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms STAY
- Sponsors Novartis Pharmaceuticals
- 03 May 2013 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 26 Mar 2013 Planned initiation date changed from 1 Oct 2012 to NULL.
- 25 Feb 2013 Status changed from not yet recruiting to completed as reported by European Clinical Trials Database record.